Monoclonal Gammopathies

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

August 12, 2025

Study Completion Date

December 31, 2025

Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS)Smoldering Multiple Myeloma (SMM)Multiple Myeloma (MM)
Interventions
OTHER

Collection of biological material

"For MGUS, SMM and MM patients, biological material (bone marrow aspirate, bone marrow biopsy, peripheral blood) consists exclusively of left-over samples obtained during routine diagnostic procedures and clinical practice management of their disease.~For healthy volunteers, biological material includes waste bone tissue obtained during orthopedic surgery (endo- or arthro-prosthesis) and peripheral blood collected for research purposes.~Both cohort of patient will be asked to donate gingival crevicular fluid (GCF) (this is a non-invasive procedure with no associated risks)."

Trial Locations (4)

Unknown

Istituto Ortopedico Rizzoli IRCCS, Bologna

"UO Ematologia Azienda Ospedaliero-Universitaria Policlinico Rodolico San Marco", Catania

"UOC di Ematologia, Dipartimento di Oncologia, AOU Policlinico Paolo Giaccone", Palermo

S.C Ematologia - Azienda USL IRCCS di Reggio Emilia, Reggio Emilia

All Listed Sponsors
collaborator

European Union Next Generation

UNKNOWN

collaborator

Ministero della Salute, Italy

OTHER

lead

Azienda USL Reggio Emilia - IRCCS

OTHER_GOV